Hostname: page-component-cd9895bd7-gvvz8 Total loading time: 0 Render date: 2024-12-28T06:23:17.609Z Has data issue: false hasContentIssue false
  • English
  • Français

Meprobamate in the Treatment of Tension States

Published online by Cambridge University Press:  08 February 2018

G. C. Heller ,
D. Walton  and
D. A. Black
G. C. Heller
Affiliation:
Rainhill Hospital, Rainhill, near Liverpool
D. Walton
Affiliation:
Rainhill Hospital, Rainhill, near Liverpool
D. A. Black
Affiliation:
Rainhill Hospital, Rainhill, near Liverpool
Get access Rights & Permissions [Opens in a new window]

Abstract

An abstract is not available for this content so a preview has been provided. Please use the Get access link above for information on how to access this content.
Image of the first page of this content. For PDF version, please use the ‘Save PDF’ preceeding this image.'
Type
Original Articles
Information
Journal of Mental Science , Volume 103 , Issue 432 , July 1957 , pp. 581 - 588
Copyright
Copyright © Royal College of Psychiatrists, 1957 

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Berger, F. M., and Ludwig, B. J., “The anticonvulsant action of 2,2-diethyl-1,3-propanediol (DEP) and some ofitshomologues and esters”, J. Pharmacol. and Exper. Therap., 1950, 100, 27.Google Scholar
Berger, F. M., and Bradley, W., “The pharmacological properties of dihydroxy-γ-(methylphenoxy)-propane (Myanesin)”, Brit. J. Pharmacol., 1946, 1, 265.Google ScholarPubMed
Ludwig, B. J., and Piech, E. C., “Some anticonvulsant agents derived from 1,3-propanediols”, J. Amer. Chem. Soc., 1951, 73, 5779.CrossRefGoogle Scholar
Berger, F. M., “The pharmacological properties of 2-methyl-2-n-propyl-1,3-propanediol bicarbamate (Miltown), a new interneuronal blocking agent”, J. Pharmacol. and Exper. Therap., 1954, 112, 413.Google Scholar
Selling, L. S., “Clinical study of a new tranquillizing drug”, J. Amer. Med. Ass., 1955, 157.Google Scholar
Borrus, J. C., “Study of effect of Miltown on psychiatric states”, ibid. Google Scholar
Collomb, H., Miletto, G., and Chaupin, M., “Meprobamate in the treatment of psychoses and neuroses”, Revue du Praticien, 1956, 1200.Google Scholar
Follin, S., Sigg, B., Pivet, S., and Girard, C., “Trials of a new tranquillizing drug”, Annales Mèdico-Psychologiques, 1956, 5.Google Scholar
Berger, F. M., “Meprobamate; its pharmacological properties and clinical uses”, Intern. Record Med. G.P. Clinics, 1956, 169, 4.Google ScholarPubMed
Lemere, F., “New tranquillizing drugs”, Northwest Medicine, 1955, 54, 1098.Google Scholar
West, E. D., and da Fonseca, A. F., “Controlled trial of meprobamate”, Brit. Med. J., 1956, ii, 1206.Google Scholar
Eysenck, H. J., Dimensions of Personality, 1947. Kegan, Paul Trench, Trubner & Co. Google Scholar
Taylor, J. A., “The relationship of anxiety to the conditioned eyelid response”, J. Exper. Psychol., 1951, 41, 81.Google Scholar
Idem , “A personality scale of manifest anxiety”, J. Abnorm. Psychol., 1953, 48.Google Scholar
Hathaway, S. R., and McKinley, J. C., Minnesota Multiphasic Personality Inventory, 1951 (revised). New York: The Psychological Corporation.Google ScholarPubMed
Lemere, F., “Habit-forming properties of meprobamate”, A.M.A. Arch. Neurol. Psychiat., 1956, 76, 205.Google Scholar
Submit a response

eLetters

No eLetters have been published for this article.